Jump to content
Retatrutide Get

Tracking what the trials actually show about retatrutide — and where its approval stands.

The papers behind the claims

Where can you check a retatrutide claim?

Start here when you want the paper itself. Each link opens a journal page or ClinicalTrials.gov, the federal list of studies.

How can you match a claim to its study?

Look for the mark [N] after a claim. The same mark on this page names the study. The list includes Phase 2 papers and Phase 3 study pages. We checked each title and link against the paper or the listing on ClinicalTrials.gov. That is the federal website for studies in people. You can open a link and check the source yourself. You can judge the paper with your own eyes.

  1. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514–526. ↗
  2. Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet. 2023;402(10401):529–544. ↗
  3. Li W, Zhou Q, Cong Z, Yuan Q, Li W, Zhao F, Xu HE, Zhao LH, Yang D, Wang MW. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discovery. 2024;10:77. ↗
  4. Urva S, Coskun T, Loh MT, Du Y, Thomas MK, Gurbuz S, Haupt A, Benson CT, Hernandez-Illas M, D'Alessio DA, Milicevic Z. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400:1869–1881. ↗
  5. Sanyal AJ, Kaplan LM, Frias JP, Brouwers B, Wu Q, Thomas MK, Harris C, Schloot NC, Du Y, Mather KJ, Haupt A, Hartman ML. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024;30:2037–2048. ↗
  6. Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide — A Game Changer in Obesity Pharmacotherapy. Biomolecules. 2025;15:796. ↗
  7. Eli Lilly and Company. A Study of Retatrutide (LY3437943) in Participants With Obesity (TRIUMPH-1). ClinicalTrials.gov. 2023. ↗
  8. Eli Lilly and Company. A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3). ClinicalTrials.gov. 2023. ↗
  9. Eli Lilly and Company. The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Function. ClinicalTrials.gov. 2024. ↗
  10. Eli Lilly and Company. A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176). ClinicalTrials.gov. 2024. ↗
  11. Eli Lilly and Company. A Study of LY3437943 in Healthy Participants. ClinicalTrials.gov. 2019. ↗
  12. Bajaj HS, et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet. 2026. ↗
  13. Elmendorf AJ, et al. IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes. Pharmacological Research. 2026. ↗
  14. et al. The First Triple Agonist for Antiobesity: Retatrutide. Clin Diabetes. 2024. ↗
  15. Drucker DJ, et al. Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity. Diabetes Care. 2024. ↗